LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

514.73 0.27

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

504.85

Max

519.75

Belangrijke statistieken
By Trading Economics
Inkomsten	-36M -94M
Verkoop	-9.7M 311M
EPS	-1.38
Winstmarge	-30.318
Werknemers	915
EBITDA	-43M -93M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+31.28% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	156M 12B
Vorige openingsprijs	514.46
Vorige sluitingsprijs	514.73

Nieuwssentiment

By Acuity

40%

60%

117 / 345 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 mei 2026, 16:33 UTC

Winsten

Belangrijke Marktbewegers

Webull Shares Slide on 1Q Loss, Soaring Costs

22 mei 2026, 21:10 UTC

Winsten

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 mei 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

22 mei 2026, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

22 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

22 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 mei 2026, 19:47 UTC

Winsten

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 mei 2026, 19:17 UTC

Marktinformatie

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 mei 2026, 19:10 UTC

Marktinformatie

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 mei 2026, 18:54 UTC

Marktinformatie

Global Equities Roundup: Market Talk

22 mei 2026, 18:54 UTC

Marktinformatie

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 mei 2026, 18:38 UTC

Marktinformatie

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 mei 2026, 18:35 UTC

Acquisities, Fusies, Overnames

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 mei 2026, 18:09 UTC

Marktinformatie

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 mei 2026, 17:58 UTC

Marktinformatie

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22 mei 2026, 17:54 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

22 mei 2026, 17:54 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

22 mei 2026, 17:54 UTC

Marktinformatie

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22 mei 2026, 17:03 UTC

Marktinformatie

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22 mei 2026, 16:54 UTC

Marktinformatie

Crypto Spot Volumes Fall 14% in April -- Market Talk

22 mei 2026, 16:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

22 mei 2026, 16:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

22 mei 2026, 16:20 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

22 mei 2026, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 mei 2026, 16:16 UTC

Marktinformatie

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22 mei 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

22 mei 2026, 15:55 UTC

Marktinformatie

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22 mei 2026, 15:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

22 mei 2026, 15:42 UTC

Marktinformatie

Oil Continues as Leading Indicator for All Markets -- Market Talk

22 mei 2026, 15:35 UTC

Marktinformatie

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

31.28% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 674.25 USD 31.28%

Hoogste 964 USD

Laagste 550 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

117 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.